IQV
NYSE · Life Sciences Tools & Services
Iqvia Holdings Inc
$185.62
+14.34 (+8.37%)
Financial Highlights (FY 2026)
Revenue
15.69B
Net Income
1.31B
Gross Margin
33.3%
Profit Margin
8.3%
Rev Growth
+4.2%
D/E Ratio
2.45
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 33.3% | 33.3% | 49.9% | 49.9% |
| Operating Margin | 13.3% | 12.0% | 10.4% | 11.9% |
| Profit Margin | 8.3% | 7.9% | 10.4% | 8.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 15.69B | 15.06B | 16.41B | 12.85B |
| Gross Profit | 5.22B | 5.01B | 8.19B | 6.41B |
| Operating Income | 2.09B | 1.81B | 1.71B | 1.53B |
| Net Income | 1.31B | 1.13B | 1.71B | 1.05B |
| Gross Margin | 33.3% | 33.3% | 49.9% | 49.9% |
| Operating Margin | 13.3% | 12.0% | 10.4% | 11.9% |
| Profit Margin | 8.3% | 7.9% | 10.4% | 8.2% |
| Rev Growth | +4.2% | +4.2% | -4.8% | -8.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 9.94B | 9.94B | 12.85B | 14.01B |
| Total Equity | 4.06B | 4.06B | 15.35B | 15.53B |
| D/E Ratio | 2.45 | 2.45 | 0.84 | 0.90 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 3.19B | 2.91B | 2.36B | 1.78B |
| Free Cash Flow | — | — | 1.51B | 1.28B |